Gastric juice protein raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-08 and is reviewed periodically as new material appears.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
== Detection and optical properties == A spectral database exists for tracking polycyclic aromatic hydrocarbons (PAHs) in the universe. Detection of PAHs in materials is often done using gas chromatography-mass spectrometry or liquid chromatography with ultraviolet-visible or fluorescence spectroscopic methods or by using rapid test PAH indicator strips. Structures of PAHs have been analyzed using infrared spectroscopy. PAHs possess very characteristic UV absorbance spectra. These often possess many absorbance bands and are unique for each ring structure. Thus, for a set of isomers, each isomer has a different UV absorbance spectrum than the others. This is particularly useful in the identification of PAHs. Most PAHs are also fluorescent, emitting characteristic wavelengths of light when they are excited (when the molecules absorb light). The extended pi-electron electronic structures of PAHs lead to these spectra, as well as to certain large PAHs also exhibiting semi-conducting and other behaviors.
On 18 July, amid the large-scale attack by Bedouin fighters on Suwayda Governorate and reports of them entering Suwayda city, backed by fighters from the neighboring Daraa Governorate and other governorates in Syria, Hikmat al-Hijri reportedly demanded the Syrian government to send a conflict resolution force. Reports later circulated that Syrian government forces were preparing to redeploy in the city of Suwayda, following renewed clashes between Druze factions and Bedouin tribes. While an Israeli government related source said that Israel had agreed to a time-limited entry into Suwayda by Syrian government forces, the Syrian Interior Ministry denied that it was preparing to re-enter the city. On 19 July, the Syrian government declared a ceasefire which was approved by the Druze leadership and Bedouin tribes. They arrived at the city of Suwayda but are having difficulty implementing the ceasefire. Fierce street fighting was documented in the city of Suwayda between Bedouins and Druze. AFP, which had teams on the ground, reported that the Bedouin militants had managed to break through the Druze defenses and penetrate the west of the city. An AFP correspondent in Suwayda reported seeing dozens of houses and cars set on fire, and gunmen setting shops on fire after looting them. On 20 July, clashes were reported after the ceasefire in the towns of Al-Ariqah, Rimah, Hazem and Shahba, after an attack by tribal militias, especially in Al-Ariqah after the entry of tribal fighters with the help of General Security Service.
In May 2016, Theranos announced that it had voided two years of results from its Edison device. The company announced that about 1% of test results had been voided or corrected from its proprietary machines in June 2016. Within two weeks, Walgreens formally terminated its partnership with Theranos and would close all remaining Theranos wellness centers. In August 2016, the company withdrew its request for emergency clearance of a Zika virus blood test after a lack of essential safeguards during the testing process was found by federal inspectors. Theranos announced that it would close its laboratory operations and wellness centers and lay off about 40% of its workforce to work on miniature medical testing machines in October 2016. In January 2017, Theranos announced that it had laid off a further 41% of its workforce, or approximately 155 people, and closed the last remaining blood-testing facility after the lab failed a second major U.S. regulatory inspection. Also that month, the company faced lawsuits from several different entities including Walgreens and Arizona Attorney General Mark Brnovich. In April 2017, lawyers for Partner Investments LP and two other funds, with combined stakes totaling more than $96 million in Theranos preferred shares, charged that Theranos had threatened to seek bankruptcy protection if the investors did not agree to accept additional stock equity in lieu of litigation. Theranos officials said the funds had mischaracterized the exchange offer, which was discussed before the suit was filed.
Sources: en.wikipedia.org
=== Second year === Reportedly, from about three dozen officers on a promotion list, most of them white men, Hegseth blocked the promotion of two women and two Black officers. According to The New York Times, "It is exceedingly rare that a one-star list draws such intense scrutiny from a defense secretary." In early 2026, reports emerged of the dismissal or retirement of several senior military commanders amid rising military tensions between the United States and Iran and broader instability in the Middle East. These developments were described as part of a broader shift in Pentagon leadership, with multiple senior officers reportedly stepping down or being removed from their positions. Media outlets reported concerns regarding internal disagreements within the defense establishment and the potential impact on the stability and operational readiness of the military command structure. Some reactions criticized the rationale for the reductions, with concerns that the large-scale removal of senior officers without clear justification could affect military readiness. In April 2026, Hegseth repealed the requirement for basic military trainees to receive the influenza vaccine. The requirement was restored in July 2026 after an outbreak at Joint Base San Antonio hospitalized four and killed one trainee. In July 2026, Hegseth announced that the military would begin testing service members' testosterone levels and providing hormone therapy. The policy was rescinded in September 2026.
Like other AASs, oxandrolone is an agonist of the androgen receptor, similar to androgens such as testosterone and DHT. The relative binding affinity of oxandrolone for the androgen receptor is about 0.3% of that of metribolone. Activation of the androgen receptor stimulates protein synthesis, which increases muscle growth, lean body mass, and bone mineral density. Compared to testosterone and many other AASs, oxandrolone is less androgenic relative to its strength as an anabolic. Oxandrolone has as much as six times the anabolic potency of testosterone and has significantly reduced androgenic potency in comparison: oxandrolone exhibits significantly lower virilizing androgenic properties compared to testosterone, with a relative androgenic potency of only 5%. Compared to methyltestosterone, oxandrolone has about 322 to 633% of the anabolic potency and 24% of the androgenic potency. The reduced ratio of anabolic to androgenic activity of oxandrolone motivated its medical use in children and women because less androgenic effect implies less risk of virilization. The bodybuilding community also considers this fact when choosing between AASs. As of 2003 and 2011 Oxandrolone was thought to be "uniquely" far less hepatotoxic than other 17α-alkylated AASs, which was thought to be due to differences in metabolism. This turned out not to be the case in the long run, which is why it was taken off the US market in 2023.
==== Illegal water extraction ==== Illegal water extraction in Iran is a significant issue, contributing to the country's water scarcity. Many influential figures, including local officials and powerful business interests, operate unauthorized wells and exploit groundwater reserves beyond legal limits. Despite regulations to control water use, enforcement is weak, leading to the depletion of critical aquifers, land subsidence, and desertification, especially in agricultural regions like Fars and Khorasan. The problem is compounded by corruption, as those with political connections often evade penalties, further undermining sustainable water management efforts. According to Mohammad Hajrasouliha, the managing director of Iran Water Resources Management Company, there are almost 320,000 illegal wells, and between 13,000 and 14,000 illegal wells are sealed yearly. The fees for water are another factor causing misuse of water.
Sources: en.wikipedia.org
Adding 60 seconds to this invasive procedure, Kahneman found participants reported the colonoscopy as more pleasant. This was attributed to making sure the colonoscopy instrument was not moved during the extra 60 seconds – movement is the source of the most discomfort. Thus, Kahneman was appealing to the remembering self's tendency to focus on the end of the experience. Such findings help explain human error in affective forecasting – people's ability to predict their future emotional states.
[C(O)NH]3 + 2 Cl2 + 2 NaOH → [C(O)NCl]2[C(O)NH] + 2 NaCl + 2 H2O This species is typically converted to its sodium salt, sodium dichloro-s-triazinetrione. Further chlorination gives trichloroisocyanuric acid, [C(O)NCl]3. These N-chloro compounds serve as disinfectants and algicides for swimming pool water. The aforementioned equilibrium stabilizes the chlorine in the pool and prevents the chlorine from being quickly consumed by sunlight.
Human genetics have been included within the field of bioethics since the early 1970s and the growth in the use of DNA sequencing (particularly high-throughput sequencing) has introduced a number of ethical issues. One key issue is the ownership of an individual's DNA and the data produced when that DNA is sequenced. Regarding the DNA molecule itself, the leading legal case on this topic, Moore v. Regents of the University of California (1990) ruled that individuals have no property rights to discarded cells or any profits made using these cells (for instance, as a patented cell line). However, individuals have a right to informed consent regarding removal and use of cells. Regarding the data produced through DNA sequencing, Moore gives the individual no rights to the information derived from their DNA. As DNA sequencing becomes more widespread, the storage, security and sharing of genomic data has also become more important. For instance, one concern is that insurers may use an individual's genomic data to modify their quote, depending on the perceived future health of the individual based on their DNA. In May 2008, the Genetic Information Nondiscrimination Act (GINA) was signed in the United States, prohibiting discrimination on the basis of genetic information with respect to health insurance and employment.
While the fair was profitable, it nevertheless left Knoxville in debt, and failed to spark the redevelopment boom Testerman, Tyree, and the fair's promoters had envisioned. Furthermore, on the day after the fair closed, the FDIC raided all of Butcher's banks, leading to the collapse of his banking empire, and threatening the city's financial stability. Testerman replaced an embattled Tyree as mayor in 1983, and attempted to reinvigorate interest in his downtown redevelopment plans.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.